Adropin and risk factors of arterial hypertension in patients with excess body weight and obesity

Introduction. Adropin is a hormone that involved in the pathogenesis of arterial hypertension (AH) and diseases cardiovascular system energy homeostasis, particular, it reduces insulin resistance by controlling glucose synthesis liver. Aim. To investigate level adropin its interaction with risk factors for AH overweight obese patients. Materials methods. 70 patients or obesity aged 62.4 ± 10.4 years were examined. 10 practically healthy people selected control group. The was determined enzyme immunoassay (Finetest Elisa Kit) blood serum. inclusion criteria participation study were: age 40–75 years; hypertension; BMI > 25 kg/m2. Results. It established average comorbid excess body weight (n = 70) 775.5 311.7 pg/ml, which significantly lower than content this peptide individuals 10), 1084.6 110.2 pg/ml (p < 0.01). A tendency towards decrease men noted. probably associated much higher prevalence smoking among category people, since when assessing contributing to development worsening prognosis, significant found persons history In (BMI 30 kg/m2), 0.05), as well pressure 150/90 mm Hg 0.05). Conclusions. serum reduced compared persons. Factors concentration include smoking, obesity, elevated levels. Blood indicators are not critical changes concentration, due medications used treat AH.